
Gasporox Q2 2023 - Sharp performance across the board

Redeye provides an update after Gasporox's Q2'23 report. We conclude the quarter was well above our expectations and that H1'23 performance was solid. We have also kicked the tires in the US and became more impressed by the product portfolio, while we expect the roll-out to be slow. We make minor adjustments to our estimates and reiterate the fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Gasporox Q2 2023 - Sharp performance across the board](#)